The two have partnered to streamline the path from cancer diagnosis to survivorship for better outcomes
Philips and Elekta today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalised cancer care through precision oncology solutions.
The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Philips and Elekta will utilise their complementary capabilities to further improve patient care.
Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalise on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.
The partnership intends to further deliver a superior experience in diagnosis, and adaptive and personalised treatments for clinicians, shorter treatment times and more precise therapy for patients and lowered costs of care for healthcare providers.
“To capitalise on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it’s essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient’s care journey,” said Kees Wesdorp, Chief Business Leader – Precision Diagnosis, Philips.
Adding to it, Gustaf Salford, Elekta’s President and CEO, said, “I expect this partnership to unlock opportunities that will provide better outcomes for people with cancer. Together, we’ll combine advanced informatics and image-guided radiation therapy solutions to deliver greater precision in oncology. This means easier selection by clinicians of the optimal treatment strategy and more efficient and effective therapy delivery.”
In this partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software in order to drive precision in oncology.